Protocol Ledger

NCT05599295 · Phase II · COMPLETED

Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections

Interventional Phase II clinical trial protocol NCT05599295 sponsored by Melinta Therapeutics in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-15 Enrollment: 118 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05599295
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)118 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05599295
Protocol FieldVerified Registry Value
NCT IdentifierNCT05599295
Consolidated Lead SponsorMelinta Therapeutics
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment118 participants (ACTUAL)
Registered Start Date2023-06-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05599295
Hospital Research SiteLocationSite Profile
Tampa General HospitalTampa, FLOpen Hospital Dossier ->
Nationwide Children's HospitalColumbus, OHOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI